Mitigating Blue-Light Risk in Display-Based Digital Therapeutics: A Practical Framework to Support Clinical Efficacy

Area of Science:

• Ophthalmology
• Chronobiology
• Digital Therapeutics

Background:

• Display-based digital therapeutics (DTx) are increasingly used for various conditions.
• The optical properties of displays significantly influence the therapeutic dose delivered.
• Blue-rich light emission (450-480 nm) can suppress melatonin and disrupt circadian timing, potentially reducing treatment efficacy.

Purpose of the Study:

• To review clinical evidence for display-enabled DTx.
• To synthesize data on blue light's effects on sleep, circadian rhythms, and related health outcomes.
• To inform spectrum optimization for therapeutic displays.

Main Methods:

• Literature review of clinical evidence for DTx.
• Synthesis of mechanistic and experimental data on blue light's biological effects.
• Distinction between retinal photochemical and melanopic hazards based on wavelength.

Main Results:

• Blue light exposure, especially in the evening, disrupts circadian rhythms and melatonin production.
• Circadian disruption is linked to adverse effects on mood, cognition, cardiovascular health, metabolism, and increased cancer/skin damage risk.
• Wavelength-specific hazards are identified: 415-450 nm (photochemical) and 450-480 nm (melanopic).

Conclusions:

• Display light characteristics are critical for DTx efficacy and safety.
• Mitigation strategies include spectrum engineering, optical filtering, and software controls.
• Aligning display output with therapeutic intent requires careful design, prescription, and standardization.